← Back
Data updated: May 24, 2026
L PERRIGO CO
Generics Pharmaceuticals
L PERRIGO CO is a generic drug manufacturer with 19 FDA-approved products.
1995
Since
19
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
Upcoming FDA Decisions
Full Calendar → May 31, 2026 — CTx-1301 (dexmethylphenidate)
5d Jun 1, 2026 — tebipenem HBr
Jun 15, 2026 — Baxdrostat
Key Drugs
Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.
Recent FDA Approvals
New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.
No recent approvals
Therapeutic Areas
Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.
No indication data
Pipeline Snapshot
Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ACETAMINOPHEN AND IBUPROFEN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (1)
Company Info
- First Approval
- 1995-11-22
- Latest
- 2025-10-22
- Applications
- 24